Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ('METRIC'): a randomized multicenter study
| Autor: | Rebecca G. Bagley, Denise A. Yardley, Volker Möbus, Abdel-Baset Halim, Rita Nanda, Gail S. Wright, Andres Forero-Torres, Thomas Hawthorne, Javier Cortes, Alberto J. Montero, Linda T. Vahdat, Kimberly L. Blackwell, Michelle E. Melisko, Melinda L. Telli, Yi He, Peter Schmid, Cynthia X. Ma, Christopher D. Turner |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Vahdat LT] Weill Cornell Medicine, New York, NY, USA. [Schmid P] Center for Experimental Cancer Medicine, Barts Cancer Institute, London, UK. [Forero-Torres A] University of Alabama School of Medicine, Birmingham, AL, USA. [Blackwell K] Duke University Medical Center, Durham, NC, USA. [Telli ML] Stanford University School of Medicine, Stanford, CA, USA. [Melisko M] University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. [Cortes J] IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Anthracycline Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] Neutropenia Other subheadings::Other subheadings::/drug therapy [Other subheadings] Article Capecitabine 03 medical and health sciences chemistry.chemical_compound Breast cancer 0302 clinical medicine Metàstasi Internal medicine Clinical endpoint medicine Pharmacology (medical) Radiology Nuclear Medicine and imaging Triple-negative breast cancer RC254-282 Cancer GPNMB business.industry Neoplasms::Neoplastic Processes::Neoplasm Metastasis [DISEASES] diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] Neoplasms. Tumors. Oncology. Including cancer and carcinogens Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] medicine.disease neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos [ENFERMEDADES] 030104 developmental biology chemistry neoplasias::procesos neoplásicos::metástasis neoplásica [ENFERMEDADES] 030220 oncology & carcinogenesis Mama - Càncer - Tractament Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms [DISEASES] Avaluació de resultats (Assistència sanitària) business Glembatumumab vedotin medicine.drug |
| Zdroj: | npj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021) Scientia NPJ Breast Cancer |
| ISSN: | 2374-4677 |
| Popis: | Breast cancer; Cancer Càncer de mama; Càncer Cáncer de mama; Cáncer The METRIC study (NCT#0199733) explored a novel antibody–drug conjugate, glembatumumab vedotin (GV), targeting gpNMB that is overexpressed in ~40% of patients with triple-negative breast cancer (TNBC) and associated with poor prognosis. The study was a randomized, open-label, phase 2b study that evaluated progression-free survival (PFS) of GV compared with capecitabine in gpNMB-overexpressing TNBC. Patients who had previously received anthracycline and taxane-based therapy were randomized 2:1 to receive, GV (1.88 mg/kg IV q21 days) or capecitabine (2500 mg/m2 PO daily d1–14 q21 days). The primary endpoint was RECIST 1.1 PFS per independent, blinded central review. In all, 327 patients were randomized to GV (213 treated) or capecitabine (92 treated). Median PFS was 2.9 months for GV vs. 2.8 months for capecitabine. The most common grade ≥3 toxicities for GV were neutropenia, rash, and leukopenia, and for capecitabine were fatigue, diarrhea, and palmar-plantar erythrodysesthesia. The study did not meet the primary endpoint of improved PFS over capecitabine or demonstrate a relative risk/benefit improvement over capecitabine. Funding provided by Celldex Therapeutics, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|